Biotech Assistant
Share useful research with your peers
in · Share on LinkedIn ↗
BIOTECH ASSISTANT / FIELD NOTES

Acuitas presents preclinical LNP data for next-generation mRNA vaccines

Company / institutional announcement · Acuitas Therapeutics

Source published:

Site published: 2026-11-03 · Updated: 2026-11-03

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗
Findings and limitationsIndustry implicationsRelated developments

What changed

Acuitas summarized World Vaccine Congress Europe data showing enhanced mRNA vaccine immune responses with ALC-315 in animal tumor models, alongside improved potency of newer lipids in an influenza vaccine model. The release describes preclinical tumor, survival, and immune-response findings. These results should not be read as demonstrated clinical efficacy or a human safety advantage.

Why it may matter

Research perspective: Lipid formulation can affect antigen presentation, dose requirements, and multivalent vaccine design. Comparisons still require matching the model, antigen, dose, and analytical methods.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

mRNA / LNP Formulation Development & Manufacturing

Follow the evidence

No explicit catalog company name was matched. These are companies in the same field, not attributed participants.

AsymchemWuXi AppTec / WuXi TIDESPorton PharmaAlmacPharmaron
Explore field companies →Explore literature →

Related updates

Nature Materials

In situ CAR engineering and nanoparticle-mediated TREM2 degradation for macrophage reprogramming in malignant ascites

A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.

mRNA / LNP In Vivo Cell Engineering & Gene Editing Protein degradation / PROTACAsk AI ↗
Moderna / ACCESS Newswire

Moderna raises 2026 revenue outlook after third-quarter growth

Moderna reported third-quarter 2026 revenue of $1.3 billion, up 29% year over year, and GAAP net income of $162 million, compared with a $200 million loss a year earlier. It raised expected full-year revenue growth to 15%–25% from up to 10%. The company attributed quarterly growth mainly to international COVID vaccine sales supported by government partnerships.

Companies mentionedModerna ↗
mRNA / LNPAsk AI ↗
Moderna (ACCESS Newswire via Newscom)

Moderna reports Canadian authorization of flu and combined flu–COVID mRNA vaccines

Moderna announced Canadian authorization of mFLUSIVA, its mRNA influenza vaccine, and mCOFLU, its combined influenza and COVID-19 vaccine, for adults 50 and older. The November 5 announcement cites Phase 3 efficacy evidence for mFLUSIVA and immunogenicity comparisons for mCOFLU. The company said it would engage Canadian authorities and immunization partners on future availability.

Companies mentionedModerna ↗
mRNA / LNPAsk AI ↗

Continue your research

All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.

Open full company map ↗
AI assistant ↗